Merus Nv

Merus NV is a global clinical-stage immuno-oncology company specialising in the development of therapies to treat cancer. Its operations focus on using human antibodies to develop a broad spectrum of tumour-targeting therapies with the aim of improving the lives of cancer patients. Operating in the biotechnology and healthcare sector, Merus NV delivers services using its proprietary Biclonics technology platform. It possesses a pipeline of multispecific antibody therapeutic candidates, referred to as Multiclonics, that are manufactured to target the mechanisms that drive cancer. Monitor the MRUS share price by adding it to your eToro watchlist.